Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

March 20, 2022

Study Completion Date

December 31, 2026

Conditions

Asthma; Eosinophilic

Interventions

DRUG

Benralizumab

Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody

DRUG

129 Xenon

1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images

Trial Locations (1)

Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre, London